Veerhealth Care

Which are the latest news on Veerhealth Care?

Why is Veerhealth Care Ltd falling/rising?

As of 05-Sep, Veerhealth Care Ltd's stock price is slightly rising to 49.76, despite underperforming its sector today and a drop in delivery volume. The stock has strong long-term performance, with year-to-date and one-year increases of 157.42% and 160.39%, respectively, and is close to its 52-week high.

As of 05-Sep, Veerhealth Care Ltd's stock price is rising slightly, with a current price of 49.76, reflecting a change of 0.09 (0.18%) upward. This increase occurs despite the stock underperforming its sector by 1.61% today and a notable decline in investor participation, as evidenced by a 16.6% drop in delivery volume compared to the 5-day average. <BR><BR>However, the stock has shown strong performance over longer periods, with a year-to-date increase of 157.42% and a one-year increase of 160.39%, significantly outperforming the Sensex, which has declined by 10.21% and 5.21% over the same periods, respectively. The stock is also close to its 52-week high, being only 4.73% away from Rs 51.84. <BR><BR>Despite the recent underperformance and falling investor participation, the overall strong historical performance and proximity to the 52-week high may contribute to a positive sentiment among investors, supporting the slight rise in the stock price.

Who are in the management team of Veerhealth Care?

The management team of Veerhealth Care includes Shruti Y Shah (Executive Director), Arvind M Shah (Independent Director), Yogesh M Shah (Chairman & Independent Director), Bhavin S Shah (Managing Director), and several other independent and non-executive directors. For more details about specific individuals or their roles, please ask!

The management team of Veerhealth Care includes the following individuals:<BR><BR>1. **Shruti Y Shah** - Executive Director<BR>2. **Arvind M Shah** - Independent Director<BR>3. **Yogesh M Shah** - Chairman & Independent Director<BR>4. **Bhavin S Shah** - Managing Director<BR>5. **Dharnendra B Shah** - Independent Director<BR>6. **Mitesh J Kuvadia** - Independent Director<BR>7. **Rony M Shah** - Company Secretary & Compliance Officer<BR>8. **Chetan H Mehta** - Non-Executive Director<BR>9. **Prakash C Shah** - Non-Executive Director<BR>10. **Nilesh Kantilal Shah** - Non-Executive Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

What does Veerhealth Care do?

Veerhealth Care Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 25 Cr and a net profit of 1 Cr for June 2026. The company, originally incorporated in 1992, has a market cap of INR 102 Cr and key financial metrics include a P/E of 54.00 and a debt-equity ratio of 0.18.

Overview:<BR>Veerhealth Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1992 as Niyati Leasing Limited, later changing its name to Niyati Industries Limited in 1998, and finally to Veerhealth Care Limited in May 2013. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 25 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 102 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 54.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.18 <BR>Return on Equity: 8.03% <BR>Price to Book: 4.42 <BR><BR>Contact Details:<BR>Address: 629-A 1st Floor Gazdar House, JSS Marg Nr Kalbadevi Post Off Mumbai Maharashtra : 400002 <BR>Tel: 91-22-22018582 <BR>Email: info@veerhealthcare.net <BR>Website: http://www.veerhealthcare.net

Who are the peers of the Veerhealth Care?

Veerhealth Care's peers include Godavari Drugs, Asston Pharmaceu, Concord Drugs, Denis Chem Lab, Mercury Labs, Amwill Health, Sunil Healthcare, Sotac Pharma, and Onyx Biotec. Veerhealth Care shows good growth and management risk, with a 1-year return of 157.30%, significantly outperforming its peers.

Peers: The peers of Veerhealth Care are Godavari Drugs, Asston Pharmaceu, Concord Drugs, Denis Chem Lab, Mercury Labs, Amwill Health, Sunil Healthcare, Sotac Pharma., and Onyx Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health, while Good management risk is found at Denis Chem Lab. Average management risk is present at Godavari Drugs, Asston Pharmaceu, Mercury Labs, and Onyx Biotec, while Below Average management risk is seen at Concord Drugs, Veerhealth Care, Sunil Healthcare, and Sotac Pharma. Growth is Good at Veerhealth Care and Sunil Healthcare, while Average growth is noted at Amwill Health and Sotac Pharma, and Below Average growth is found at Godavari Drugs, Asston Pharmaceu, Concord Drugs, Denis Chem Lab, Mercury Labs, and the rest. Capital Structure is Excellent at Denis Chem Lab and Amwill Health, Good at Veerhealth Care, Average at Asston Pharmaceu, Sotac Pharma, and Onyx Biotec, and Below Average at Godavari Drugs, Concord Drugs, Mercury Labs, and Sunil Healthcare.<BR><BR>Return Snapshot: Veerhealth Care has a 1-year return of 157.30%, which is higher than the highest peer return of 29.93% from Concord Drugs and significantly higher than the lowest peer return of -24.43% from Denis Chem Lab. Additionally, Denis Chem Lab, Mercury Labs, and Amwill Health have negative six-month returns.

How big is Veerhealth Care?

As of 31st August, Veerhealth Care Ltd has a market capitalization of 102.00 Cr, with recent net sales of 52.93 Cr and a net profit of 1.53 Cr. Shareholder's funds are 22.22 Cr, and total assets are valued at 33.77 Cr as of March 2025.

As of 31st August, Veerhealth Care Ltd has a market capitalization of 102.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Veerhealth Care reported Net Sales of 52.93 Cr and a Net Profit of 1.53 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 22.22 Cr and Total Assets valued at 33.77 Cr.

Should I buy, sell or hold Veerhealth Care Ltd?

When is the next results date for Veerhealth Care Ltd?

The next results date for Veerhealth Care Ltd is 13 August 2026.

The next results date for Veerhealth Care Ltd is scheduled for 13 August 2026.

Are Veerhealth Care Ltd latest results good or bad?

Veerhealth Care Ltd's latest results show strong revenue growth with a 130.85% increase in net sales quarter-on-quarter, but the company reported a net loss of ₹0.35 crores and a significant decline in profit margins, indicating challenges in maintaining profitability. Investors should approach with caution due to these mixed signals.

Veerhealth Care Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable 130.85% increase in net sales quarter-on-quarter, reaching ₹16.76 crores, and a significant 198.22% increase year-on-year. This growth indicates strong topline momentum, which is a positive sign for the company.<BR><BR>However, the financial performance is marred by a net loss of ₹0.35 crores in Q4 FY26, a stark contrast to the profit of ₹0.40 crores reported in the previous quarter. This loss, coupled with a drastic decline in profit margins—operating margin fell to 4.36% from 17.08%—raises concerns about the company's ability to convert revenue growth into sustainable profits. Additionally, the extraordinary tax charge leading to an effective tax rate of 294.44% further complicates the earnings picture, suggesting potential issues with earnings quality.<BR><BR>Overall, while the revenue growth is impressive, the inability to maintain profitability and the significant margin compression indicate that investors should approach Veerhealth Care with caution. The results highlight both potential and challenges, making it a high-risk investment at this stage.

How has been the historical performance of Veerhealth Care?

Veerhealth Care's historical performance shows net sales growth from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, but profitability has fluctuated, with profit after tax declining from 1.58 Cr in Mar'23 to 0.39 Cr in Mar'25. Total assets increased significantly, while cash flow from operating activities dropped to 0.00 Cr in Mar'25.

Answer:<BR>The historical performance of Veerhealth Care shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Veerhealth Care's net sales have increased from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, rising from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25. The company's total expenditure also grew, reaching 16.21 Cr in Mar'25 from 10.45 Cr in Mar'22. Operating profit (PBDIT) fluctuated, peaking at 2.00 Cr in Mar'24 before dropping to 1.68 Cr in Mar'25. Profit before tax showed variability, with a notable increase to 1.28 Cr in Mar'24 but declining to 0.51 Cr in Mar'25. Profit after tax was 0.39 Cr in Mar'25, down from 1.58 Cr in Mar'23. The company's total assets increased significantly from 20.15 Cr in Mar'22 to 33.77 Cr in Mar'25, while total liabilities also rose from 20.15 Cr to 33.77 Cr in the same period. Cash flow from operating activities was 0.00 Cr in Mar'25, contrasting with 2.00 Cr in Mar'24, while cash flow from investing activities showed a negative trend at -8.00 Cr in Mar'25. Overall, Veerhealth Care's financial performance reflects both growth in sales and assets, alongside challenges in profitability and cash flow management.

Who are the top shareholders of the Veerhealth Care?

The top shareholder of Veerhealth Care is Yogesh Mahasuklal Shah, with an 11.03% stake, followed by public shareholder Deval Nilay Shah at 2.68%. Individual investors collectively own 57.92% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Veerhealth Care include Yogesh Mahasuklal Shah, who holds the highest stake at 11.03%. The highest public shareholder is Deval Nilay Shah, with a holding of 2.68%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 57.92% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Is Veerhealth Care overvalued or undervalued?

As of February 13, 2025, Veerhealth Care is considered overvalued with a PE ratio of 30.00 and an EV to EBITDA of 33.75, despite recent strong stock performance, indicating a shift in sentiment from very expensive to risky compared to peers like Elitecon International and Lloyds Enterprises.

As of 13 February 2025, Veerhealth Care's valuation grade has moved from very expensive to risky, indicating a shift in investor sentiment. The company is currently assessed as overvalued. Key ratios include a PE ratio of 30.00, an EV to EBITDA of 33.75, and a ROE of 1.76%. <BR><BR>In comparison to its peers, Veerhealth Care's PE ratio is significantly lower than that of Elitecon International, which stands at 131.08, and also lower than Lloyds Enterprises at 156.59. However, it is on par with MMTC, which has a PE ratio of 119.39. Notably, the company's recent stock performance has outpaced the Sensex in the short term, with a 1-week return of 9.80% compared to the Sensex's 1.43%. This suggests some short-term investor interest, but the overall valuation still leans towards overvaluation given the broader financial metrics.

What is the technical trend for Veerhealth Care?

As of May 12, 2025, Veerhealth Care shows a mildly bearish trend overall, with mixed indicators suggesting short-term weakness despite a current price of 16.47, which is above the previous close of 15.00.

As of 12 May 2025, the technical trend for Veerhealth Care has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD indicates a mildly bearish stance. The moving averages on a daily basis are also mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish monthly. The KST reflects a mildly bullish trend weekly while being mildly bearish monthly. Overall, the indicators present a mixed picture, with a slight bearish bias prevailing in the longer term. The current price of 16.47 is above the previous close of 15.00, but the stock has underperformed significantly over the past year. The overall stance is mildly bearish with moderate strength.

What is the bonus history of the Veerhealth Care?

Veerhealth Care recently issued a 1:1 bonus share on September 22, 2023, meaning shareholders received an additional share for each share held. The record date for this bonus was also September 22, 2023.

Veerhealth Care has a recent bonus history that includes a 1:1 bonus issue announced with an ex-date of September 22, 2023. This means that for every share held, shareholders received an additional share. The record date for this bonus was also September 22, 2023. If you have any more questions about Veerhealth Care or need further details, feel free to ask!

Has Veerhealth Care declared dividend?

No Dividend History Available